《生命科学》 2014, 26(8): 829-834

凝溶胶蛋白治疗阿尔茨海默症的研究进展

吉丽娜*，赵　熙，华子春*

(南京大学生命科学学院医药生物技术国家重点实验室，南京 210093)

摘　要：摘　要：阿尔茨海默症(Alzheimer’s disease， AD) 的病理学特征之一是患者脑内存在以β- 淀粉样肽(Aβ) 为主要成分的老年斑。大量的实验证据表明，以Aβ 为靶目标，清除老年斑有助于提高患者的认知能力，是防治AD 的一个重要研究方向。凝溶胶蛋白在细胞骨架结构重排和细胞运动等过程中都发挥重要作用。目前多个小组的研究成果显示，凝溶胶蛋白与AD 的发生、发展密切相关。凝溶胶蛋白能够抑制Aβ 积聚形成纤维，也能够引发已形成的Aβ 纤维发生解聚。更重要的是，凝溶胶蛋白能够清除转基因AD 模型小鼠脑内的老年斑和降低Aβ 的水平。未来凝溶胶蛋白有可能被应用于AD 的预防和治疗。

Recent advances in the treatment of Alzheimer's disease by gelsolin

JI Li-Na*， ZHAO Xi， HUA Zi-Chun*

(The State Key Laboratory of Pharmaceutical Biotechnology， College of Life Sciences， Nanjing University， Nanjing 210093， China)

Abstract: Abstract: The presence of amyloid plaques is one of the neuropathological features of Alzheimer's disease (AD). Amyloid plaques consist mainly of β-amyloid peptide (Aβ). Accumulating evidence shows， targeting Aβ， clearance of amyloid plaques is helpful for improving recognition ability， and will be an important strategy for the treatment of AD. Gelsolin plays an important role in the regulation of cell skeleton rearrangement and cell mobility. Results from several research groups show that gelsolin is closely related to the pathogenesis and development of AD. Gelsolin inhibits the aggregation of Aβ into fibrils， and also disaggregates the preformed Aβ fibrils. More importantly， gelsolin reduces amyloid plaques and decreases the level of Aβ in transgenic mouse models of AD. In the future， gelsolin will be probably applied in the prevention and treatment of AD.